ArticleNature medicine2023
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer.
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03297034 (Swiss Childhood Cancer Survivor Study), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Swiss Childhood Cancer Survivor Study (SCCSS)
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Breast cancer incidence and mortality in population studies of radiation exposure: systematic review and meta-analysis.British journal of cancer · 2026Pooled it
- Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol.Human reproduction (Oxford, England) · 2024Trial
- Association of age and primary treatment with risk of non-lymphoma-related death and long-term survival outcomes in adult patients with early-stage follicular lymphoma: a population-based analysis.Annals of hematology · 2026Article
- Novel Insights into the Role of circRNAs in Cancer Immunotherapy Resistance and Clinical Implications.International journal of molecular sciences · 2026Review
- Chemo-/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies.Pediatric blood & cancer · 2026Article
- Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy.Acta oncologica (Stockholm, Sweden) · 2025Article
- Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.medRxiv : the preprint server for health sciences · 2025Article
- Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma.Nature medicine · 2025Article
- Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma.Journal of the National Cancer Institute · 2025Article
- Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer.Nature communications · 2025Article
- Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy.Nature reviews. Cancer · 2025Review
- Review
- Article
- Aging and cancer.Molecular cancer · 2024Review
- Effectiveness and Cost-Effectiveness of Survivorship Care for Survivors of Hodgkin Lymphoma (INSIGHT Study): Protocol for a Multicenter Retrospective Cohort Study With a Quasi-Experimental Design.JMIR research protocols · 2024Article
- Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma.Research square · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 20 institutions in 7 countries.
Funding
Abstract
Anthracycline-based chemotherapy is associated with increased subsequent breast cancer (SBC) risk in female childhood cancer survivors, but the current evidence is insufficient to support early breast cancer screening recommendations for survivors treated with anthracyclines. In this study, we pooled individual patient data of 17,903 survivors from six well-established studies, of whom 782 (4.4%) developed a SBC, and analyzed dose-dependent effects of individual anthracycline agents on developing SBC and interactions with chest radiotherapy. A dose-dependent increased SBC risk was seen for doxorubicin (hazard ratio (HR) per 100 mg m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.